TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04892628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic training
Description: The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
Study: NCT06421545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Together for Dementia
Description: A novel live video dyadic resiliency intervention
Study: NCT06056804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825-1000mg/m2,po,bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: 200mg,iv.gtt,q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymalfasin
Description: 4.8mg,sc,biw

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: long-term radiotherapy
Description: 50 Gy/25 f, 2 Gy/day
Study: NCT05234879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame Running
Description: Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
Study: NCT04878432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Solution for subcutaneous injection or intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INQOVI (oral decitabine)
Description: Tablet for oral administration
Study: NCT05269888

Intervention type: OTHER
Intervention: Blood Test 1
Description: Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres

Intervention type: OTHER
Intervention: Blood Test 1
Description: Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres
Study: NCT06469411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)
Description: Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4 cc distilled water dissolved in albumin 20%
Description: Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
Study: NCT04913337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Study: NCT05581498

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, Bike exercise and muscle strength exercise.
Description: Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, Bike exercise and muscle strength exercise.
Description: Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks.
Study: NCT04117074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (bupivacaine)
Description: Perioperative bupivacaine based thoracic epidural placed preoperatively.
Study: NCT05960227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron dextran
Description: Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250ml of saline 0,9% for 4 hours insusion.
Study: NCT05766488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: A continuous glucose monitor will be provided in the experimental arm of this study for 6 months. This monitor will be a Freestyle Libre 2 device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional glucometer
Description: A traditional glucometer device will be assigned in the standard of care arm of this study for 6 months.
Study: NCT05129293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective Memory Intervention
Description: Cognitive remediation focusing on prospective memory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational
Description: Psychoeducation
Study: NCT05740176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
Study: NCT06647979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein
Description: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequencing Assay for Variant rs114518452
Description: Device used to carry out the diagnostic testing for exclusion criteria number 12
Study: NCT06647745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THP-00101
Description: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: THP-00101
Description: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THP-00101
Description: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THP-00102
Description: Telmisartan 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THP-00102
Description: Telmisartan 80 mg

Intervention type: DRUG
Group type: OTHER
Intervention: THP-00103
Description: Telmisartan 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THP-00104
Description: Placebo of Dapagliflozin 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THP-00104
Description: Placebo of Dapagliflozin 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THP-00105
Description: Placebo of Telmisartan 80mg

Intervention type: DRUG
Group type: OTHER
Intervention: THP-00105
Description: Placebo of Telmisartan 80mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THP-00106
Description: Placebo of Telmisartan 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THP-00106
Description: Placebo of Telmisartan 40mg
Study: NCT06648941

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle release
Description: supraspinatus muscle release
Study: NCT06117709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-STAMP
Description: A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.
Study: NCT05477212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: all patients will receive a very low calorie ketogenic diet
Study: NCT05481593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Coaching + Gamified Rewards
Description: Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Coaching Calls + Independent Rewards
Description: Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Scheduled Coaching Calls + Gamified Rewards
Description: Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Scheduled Coaching Calls + Independent rewards
Description: Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
Study: NCT06485349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Leaf Extract (OLE)
Description: Daily dose of 750mg OLE consumed with water after breakfast without any modification of their dietary patterns for 90 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg microcrystalline cellulose
Study: NCT05963633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Description: The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Episodic Recent Thinking (ERT)
Description: In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
Study: NCT05617638

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
Study: NCT06511206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25g MCT-based nutrient mix
Description: The 25g MCT-based nutrient mix will be consumed two hours after breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25g MCT-based nutrient mix + cofactors
Description: The 25g MCT-based nutrient mix + cofactors will be consumed two hours after breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: non-ketogenic control
Description: The non-ketogenic control will be consumed two hours after breakfast.
Study: NCT05333939

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa leaf powder
Description: capsule ingestion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule ingestion
Study: NCT06566209

Intervention type: DEVICE
Intervention: Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)
Description: Receive 18F-FDG PET/CT
Study: NCT06060613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBX-115
Description: A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by a short course of acetazolamide.
Study: NCT04087629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataCTX® gel
Description: Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataCTX® gel
Description: Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
Study: NCT05142150

Intervention type: OTHER
Intervention: Questionaire
Description: Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying.

Intervention type: OTHER
Intervention: Questionaire
Description: Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying.
Study: NCT05972291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Glutamine
Description: You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
Study: NCT04781543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-825 BID
Description: 300 mg oral tablets BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT05972291

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Arm
Description: You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
Study: NCT05356962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StOP?-protocol
Description: The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
Study: NCT05619536

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection
Study: NCT05721248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of anti-HER2 treatment
Description: Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
Study: NCT06575660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health support session
Description: a single AI-VR mental health support session using the XAIA application
Study: NCT05666414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sandwich interpositional bone grafting computer guided
Description: performing the 2 vertical and the 1 horizontal osteotomies using a cutting patient specific guide and fixation of the vertically elevated bony segment after gap calculation using patient specific fixation guides

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional interpositional bone grafting
Description: performing the conventional interpositional sandwich osteotomies free-hand and fixation of the mobilized bone segment free-hand
Study: NCT05314140

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary artery calcium score evaluation
Description: The evaluation of the coronary artery calcium score will be performed with chest CT scan
Study: NCT05284292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUARDIAN platform
Description: The enrolled elderly subjects and their caregivers will use at home the GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot.
Study: NCT05714046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: An informative presentation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga training
Description: Yoga exercise training
Study: NCT04781543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-825 QD
Description: 300 mg oral tablets QD
Study: NCT05289375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vacucis autovaccine
Description: A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
Study: NCT05616117

Intervention type: OTHER
Intervention: Intrauterine 90µg D-vitamin
Description: Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3

Intervention type: OTHER
Intervention: Intrauterine 10µg D-vitamin
Description: Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
Study: NCT05525988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction
Description: Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on.
Study: NCT05012904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent involvement application
Description: A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.